FDA Approved Two New Treatments for Depression

Federal regulators have greenlit gepirone ER and lumateperone to treat major depressive disorder in patients.

Updated on Oct. 12, 2026 in Alzheimer’s

FDA Approved Two New Treatments for Depression

Live Poll

Do you feel that new drug approvals for depression provide better treatment options for your household?

The FDA recently granted approval for two new medications, gepirone ER and lumateperone, to treat major depressive disorder. These treatments offer new options for patients as the medical community continues to address mental health needs.

Why it matters

The approval of these drugs expands the available pharmacological toolkit for clinicians treating depression. Providing additional therapeutic options is essential for tailoring care to individual patient needs and improving overall clinical outcomes.

A six-month study of lumateperone demonstrated an 80% response rate and a 65% remission rate. Lumateperone is administered in 21 mg or 42 mg daily doses, while gepirone ER requires dose titration.

The players

FDA

The Food and Drug Administration is the federal agency responsible for protecting public health by ensuring the safety and efficacy of medications.

The details

Gepirone ER has been noted for its ability to treat major depressive disorder without causing sexual dysfunction, a common side effect of many existing antidepressants. Lumateperone is approved as an adjunctive treatment and is administered once daily.

The official report regarding these two drug approvals was published in October 2026.

Health Landscape

These approvals represent the latest milestone in the evolution of psychiatric care and the FDA drug approval process. This expansion of available treatments mirrors ongoing shifts toward more diverse pharmacological options for managing mental health.

Patients may now discuss these new medication options with their healthcare providers to determine if they are suitable for their specific treatment plan. These drugs offer alternative pathways to address symptoms, potentially reducing common side effects like sexual dysfunction.

The takeaway

Patients should work closely with their medical providers to understand the dosing requirements and potential benefits of these new psychiatric medications. Consistent communication with a doctor remains the most effective way to monitor treatment progress and safety.